Table 3.
Concept prevalence concepts missing from the OMOP2OBO mapping set.
| OMOP domain | Concept | Concept labela | Average concept frequencyb | Study sites |
|---|---|---|---|---|
| Condition | 4,091,502 | Increased fluid intake | 100,483.0 | 1 |
| 37,311,061 | COVID-19 | 93,585.0 | 1 | |
| 40,443,308 | Polycystic ovary syndrome | 62,900.3 | 3 | |
| 35,615,055 | Saddle embolus of pulmonary artery with acute cor pulmonale | 22,324.4 | 10 | |
| 36,684,319 | Adjustment disorder with mixed anxiety and depressed mood | 18,453.0 | 1 | |
| Drug Ingredient | 37,498,625 | Hepatitis A virus strain CR 326F antigen, inactivated | 175,551.3 | 14 |
| 1,510,467 | Erenumab | 60,618.0 | 10 | |
| 35,200,577 | Fremanezumab | 15,579.6 | 5 | |
| 35,200,800 | Galcanezumab | 11,594.8 | 5 | |
| 35,201,105 | Baloxavir marboxil | 11,366.7 | 3 | |
| Measurement | 3,045,980 | Pulse intensity of Unspecified artery palpation | 1,219,846,862.0 | 1 |
| 3,021,716 | Penicillin G potassium [Mass] of Dose | 253,609,945.0 | 1 | |
| 40,760,098 | Sodium [Moles/volume] in Saliva (oral fluid) | 246,641,311.0 | 1 | |
| 3,045,820 | Cotinine/Creatinine [Mass Ratio] in Urine | 246,063,202.0 | 1 | |
| 3,008,500 | Chloride [Moles/volume] in Saliva (oral fluid) | 234,931,483.0 | 1 |
OMOP Observational Medical Outcomes Partnership.
aConcept labels were obtained from the Athena web application (https://athena.ohdsi.org/) on 12/29/2022.
bThe average concept frequency was calculated as the frequency of each concept divided by the number of Concept Prevalence study sites with that concept by each clinical domain.